- NEWS FEATURE
- Correction 15 February 2024
Researchers are blasting patients’ cancer cells with dozens of drugs in the hope of finding the right treatment.
By
-
Elie Dolgin
-
Elie Dolgin is a science journalist in Somerville, Massachusetts.
-
Illustration: Shira Inbar
The blood cancer had returned, and Kevin Sander was running out of treatment options. A stem-cell transplant would offer the best chance for long-term survival, but to qualify for the procedure he would first need to reduce the extent of his tumour — a seemingly insurmountable goal, because successive treatments had all failed to keep the disease in check.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 626, 470-473 (2024)
doi: https://doi.org/10.1038/d41586-024-00392-2
Updates & Corrections
-
Correction 15 February 2024: An earlier version of this feature stated that Philipp Staber’s lab uses a 386-well plate.
References
Kornauth, C. et al. Cancer Discov. 12, 372–387 (2022).
Snijder, B. et al. Lancet Haematol. 4, e595–e606 (2017).
O’Dwyer, P. J. et al. Nature Med. 29, 1349–1357 (2023).
Malani, D. et al. Cancer Discov. 12, 388–401 (2022).
Ranjan, T. et al. Cell Rep. Med. 4, 101025 (2023).
Ranjan, T. et al. Neurooncol Adv. 5, vdad055 (2023).
Manzano-Muñoz, A. et al. npj Precis. Oncol. 6, 90 (2022).
Mayoh, C. et al. Cancer Res. 83, 2716–2732 (2023).
Al-Aloosi, M. et al. Front. Oncol. 13, 1267650 (2024).
Gray, H. J. et al. npj Precis. Oncol. 7, 45 (2023).
Bangi, E. et al. iScience 24, 102212 (2021).
Bangi, E. et al. Sci. Adv. 5, eaav6528 (2019).
Tsai, L. L. et al. Ann. Surg. 277, e1143–e1149 (2023).
Peruzzi, P. et al. Sci. Transl. Med. 15, eadi0069 (2023).
Related Articles
-
The mice with human tumours: Growing pains for a popular cancer model
-
Super-precise CRISPR tool enters US clinical trials for the first time
-
CRISPR cancer trial success paves the way for personalized treatments
Is precision public health the future — or a contradiction?